학술논문
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen
Document Type
Article
Author
Palich, R.; Tubiana, R.; Dudoit, Y.; Katlama, C.; Allavena, C.; Peytavin, G.; Lê, M.-P.; Marcelin, A.-G.; Soulie, C.; Weiss, L.; Montoya Ferrer, A.; Duvivier, C.; Bouchaud, O.; Bottero, J.; Assoumou, L.; Durand, A.; Allavena, C.; Raffi, F.; Cavellec, M.; Soria, A.; Manyari, E.P.; Reynes, J.; Ferrer, A.M.; Tramoni, C.; Fernandez, C.; Duvivier, C.; Lourenço, J.; Louisin, C.; Touam, F.; Bouchaud, O.; Traore, L.; Bottero, J.; Kaykay, F.M.; Benmammar, A.; Weiss, L.; Effa, J.; Ptak, M.; Valantin, M.A.; Tubiana, R.; Schneider, L.; Blanc, C.; Lenclume, L.
Source
In: Journal of Antimicrobial Chemotherapy . (Journal of Antimicrobial Chemotherapy, 1 February 2021, 76(2):477-481)
Subject
Language
English
ISSN
14602091
03057453
03057453